More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$676403190
EPS
-3.1
P/E ratio
--
Price to sales
1.85
Dividend yield
--
Beta
0.99982
Previous close
$24.08
Today's open
$24.12
Day's range
$23.39 - $24.23
52 week range
$13.46 - $31.04
show more
CEO
Ming Hsieh
Employees
1315
Headquarters
El Monte, CA
Exchange
NASDAQ Global Market
Shares outstanding
27939000
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
Fulgent Genetics (FLGT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Fulgent Genetics (FLGT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks Investment Research • 11 hours ago

Fulgent Genetics, Inc. (FLGT) Q3 2026 Earnings Call Transcript
Fulgent Genetics, Inc. ( FLGT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lauren Sloane - The Blueshirt Group, LLC Karan Patel - Piper Sandler & Co., Research Division Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Fulgent Genetics Q3 2026 Conference Call and Webcast Call. [Operator Instructions] This call is being recorded on Thursday, November 5, 2026.
Seeking Alpha • Nov 6, 2026

What Fulgent Genetics (FLGT) Said on Its Q3 Earnings Call
Fulgent Genetics NASDAQ: FLGT reported third-quarter revenue of $90.4 million, up 8% from a year earlier, as contributions from Bako Diagnostics and StrataDx and improving collections helped lift results. The company reaffirmed its full-year revenue forecast and narrowed its projected loss.
MarketBeat • Nov 6, 2026

Fulgent Reports Third Quarter 2026 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2026. Third Quarter 2026 Results: Revenue of $90.4 million GAAP loss of $13.2 million, or $(0.48) per share Non-GAAP loss of $2.4 million, or $(0.09) per share Adjusted EBITDA loss of $7.5 million No.
Business Wire • Nov 5, 2026

Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Beats Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to earnings of $0.14 per share a year ago.
Zacks Investment Research • Nov 6, 2026

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer q.
Business Wire • Oct 15, 2026

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.
Zacks Investment Research • Sep 22, 2026

Think Outside the Box With These 3 Companies That Make Unusual Business Models Work
Some of the most successful companies started with business models that likely seemed unusual at first. Investors willing to take a chance on what may appear to be a quirky approach could find a surprisingly strong set of financials and a compelling case for future growth.
MarketBeat • Sep 21, 2026

Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Seeking Alpha • Jul 31, 2026

Fulgent Genetics Q2 Earnings Call Highlights
Fulgent Genetics NASDAQ: FLGT reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower collection rates during a transition to a new billing and revenue-cycle-management system.
MarketBeat • Jul 30, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Fulgent Genetics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.